Abstract
The administration of pyridoxine-alpha-ketoglutarate (PAK) to type I and II diabetics previously treated with insulin and phenformin, reduces blood glucose, HbA1, and blood levels of lactate and pyruvate. The results of this double-blind clinical trial showed that PAK is advantageous for improving certain metabolic aspects in diabetics.
Original language | English |
---|---|
Pages (from-to) | 252-256 |
Number of pages | 5 |
Journal | International Journal of Clinical Pharmacology Therapy and Toxicology |
Volume | 21 |
Issue number | 5 |
Publication status | Published - 1983 |
ASJC Scopus subject areas
- Toxicology
- Pharmacology (medical)